Repare Therapeutics Inc. (RPTX) is an innovative biotechnology firm based in Montreal, Canada, focused on transforming cancer treatment through precision oncology and synthetic lethality strategies. The company specializes in developing targeted therapies that leverage the unique genetic vulnerabilities of tumors, thereby addressing significant unmet needs in the oncology field. With a strong pipeline of advanced drug candidates, Repare is well-positioned to significantly impact the future of cancer care, contributing to the rapid evolution of precision medicine in a growing global market. Show more

Location: 7171 FREDERICK-BANTING, BUILDING 2, MONTREAL, QC, CANADA, H4S 1Z9, Montreal, QC, H4S 1Z9, USA | Website: https://www.reparerx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

114.2M

52 Wk Range

$0.89 - $2.66

Previous Close

$2.65

Open

$2.65

Volume

N/A

Day Range

$2.65 - $2.65

Enterprise Value

1.975M

Cash

72.83M

Avg Qtr Burn

N/A

Insider Ownership

0.25%

Institutional Own.

64.15%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lunresertib (RP-6306) +/- Camonsertib (RP-3500) or Debio 0123 Details Ovarian cancer, Endometrial cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lunresertib (RP-6306) + gemcitabine Details Cancer, Advanced malignancies	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Camonsertib (RP-3500) +/- radiotherapy Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP-1664 Details Cancer, Neuroblastoma	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP-1664 Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP-3467 +/- olaparib Details Cancer, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lunresertib (RP-6306) + FOLFIRI Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lunresertib (RP-6306) + gemcitabine Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.